Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.63 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.63 |
| ▸ | FLT3 | P36888 | 3/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.56 |
| ▸ | CSF1R | P07333 | 2/20 | 0.56 |
| ▸ | CLK2 | P49760 | 2/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.56 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.56 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.56 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.56 |
| ▸ | FER | P16591 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | MARK3 | P27448 | 1/20 | 0.56 |
| ▸ | FLT4 | P35916 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL730582 | 0.98 | JAK2 (0.61) | JAK2PDPK1FLT3CLK4DYRK1A | |
| Hydrazine SCHEMBL5316054 | 0.96 | JAK2 (0.65) | JAK2PDPK1FLT3CLK4DYRK1A | |
| SCHEMBL4516170 | 0.86 | PDPK1 (0.49) | JAK2PDPK1FLT3CLK4DYRK1A | |
| SCHEMBL16795434 | 0.85 | CYP1A2 (0.59) | JAK2PDPK1FLT3CLK4DYRK1A | |
| SCHEMBL11034 | 0.84 | PDPK1 (0.63) | JAK2PDPK1FLT3CLK4DYRK1A | |
| SCHEMBL29502106 | 0.84 | PDPK1 (0.63) | JAK2PDPK1FLT3CLK4DYRK1A | |
| Hydrochloric Acid SCHEMBL31271568 | 0.84 | CYP1A2 (0.57) | JAK2PDPK1FLT3CLK4DYRK1A | |
| Tert-Butyl Formate SCHEMBL27702956 | 0.83 | PDPK1 (0.46) | JAK2PDPK1FLT3CLK4DYRK1A | |
| SCHEMBL2731639 | 0.79 | FLT3 (0.75) | JAK2PDPK1FLT3CLK4DYRK1A | |
| SCHEMBL30855645 | 0.79 | PDPK1 (0.68) | JAK2PDPK1FLT3CLK4DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055363-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4724438-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4688149-A1 | IRAK4 PROTACS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | TERNS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4608507-A1 | COMPOUNDS AND COMPOSITIONS AS GPR52 MODULATORS | Neurocrine Biosciences, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250163189-A1 | RAFT AGENT FOR PHOTO-CONTROLLED POLYMERIZATION, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | SHANDONG UNIVERSITY (CN) | 2025-05-22 | — | — | US | disclosed |
| WO-2025106910-A1 | DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR | FLARE THERAPEUTICS INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025096710-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | AMGEN INC. | 2006-07-13 | — | — | US | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006044860-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | JAK2 356/4885PDPK1 84/4885FLT3 527/4885 |
| US-20250163189-A1 | RAFT AGENT FOR PHOTO-CONTROLLED POLYMERIZATION, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | WASF2, RFTN1, WEE2 | JAK2 3826/4885PDPK1 3747/4885FLT3 833/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | JAK2 356/4885PDPK1 84/4885FLT3 527/4885 |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | JAK2 897/4885PDPK1 3534/4885FLT3 1845/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | JAK2 2617/4885PDPK1 1104/4885FLT3 1988/4885 |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | JAK2 955/4885PDPK1 1024/4885FLT3 4313/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | JAK2 472/4885PDPK1 1453/4885FLT3 1059/4885 |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | JAK2 34/4885PDPK1 6/4885FLT3 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.